Source comparison
Tesamorelin + Ipamorelin Blend History: Comparison Table
The following table compares the characteristics of Tesamorelin and Ipamorelin individually, then summarizes their combined profile in the blend. Mechanism of Action Synthetic GHRH analogue; binds GHRH receptors on pituitary somatotrophs to stimulate endogenou
This comparison does not assign a generated winner or score.
- The following table compares the characteristics of Tesamorelin and Ipamorelin individually, then summarizes their combined profile in the blend.
- Mechanism of Action
- Synthetic GHRH analogue; binds GHRH receptors on pituitary somatotrophs to stimulate endogenous GH release
- Selective ghrelin receptor (GHS-R1a) agonist; mimics ghrelin action without appetite or cortisol effects
- Dual-pathway stimulation: GHRH receptor activation plus ghrelin receptor activation produce synergistic GH release
- The blend leverages two independent pathways for amplified effect. Mechanistic synergy is well-documented in published trials
- FDA Approval Status
- FDA-approved (Egrifta) for HIV-associated lipodystrophy; compounded versions not FDA-approved
- Never FDA-approved; used extensively in research contexts
- Neither combination nor individual compounded forms are FDA-approved
- Compounded peptides are legal and widely used but lack FDA endorsement. Distinction matters for regulatory compliance
- Half-Life
- Approximately 26–38 minutes after subcutaneous injection
- Approximately 2 hours after subcutaneous injection
- Functional coverage spans 2+ hours when dosed together
- Staggered half-lives provide sustained receptor occupancy without requiring continuous infusion
- Dosing Frequency
- Typically once daily (evening or pre-bed)
- Typically twice daily (morning and evening) or three times daily in research protocols
- Combined: once daily Tesamorelin + twice daily Ipamorelin is the most common protocol
- Dosing flexibility allows alignment with natural GH pulsatility (highest during sleep)
- Side Effect Profile
- Injection site reactions, arthralgia, peripheral edema, mild glucose elevation
- Minimal side effects; occasional flushing or mild headache reported
- Additive profile with no adverse interactions; glucose monitoring recommended
- The safety profile is favorable compared to exogenous GH administration. Preserved negative feedback reduces risk of supraphysiological levels
- Target Patient Population (Research)
- Metabolic research in aging populations; visceral adiposity; GH deficiency contexts
- Body recomposition research; athletic performance studies; age-related GH decline
- Comprehensive metabolic optimization research combining body composition and longevity markers
- The blend is most appropriate for research contexts requiring robust GH stimulation without exogenous hormone replacement